Objective: Preoperative anemia and blood transfusions are associated with worse outcomes after surgery. However, the impact of preoperative anemia and transfusions on outcomes after carotid endarterectomy (CEA) is unknown.
Results: Of 16,068 patients, 6734 (42%) were symptomatic, of whom 1500 (22%) had anemia. Of the 9334 asymptomatic patients, 1935 (21%) had anemia. Both symptomatic and asymptomatic anemic patients were more likely to be transfused perioperatively compared with nonanemic patients, with 7.0% vs 0.4%, and 5.8% vs 0.7% (both P < .001). Among symptomatic patients, those with anemia compared with those without had a higher rate of 30-day mortality (2.5% vs 0.7%; P < .001). After adjustment, anemic symptomatic patients had a higher 30-day mortality risk (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.9-5.0; P < .001) compared with nonanemic symptomatic patients. In addition, in symptomatic patients, we found a significant interaction between anemia and perioperative transfusion on the outcome of 30-day mortality (P ¼ .004), with a higher risk in perioperatively transfused symptomatic patients with anemia (OR, 7.8; 95% CI, 3.4-18.0; P < .001) than in symptomatic patients with anemia who did not receive a perioperative transfusion (OR, 2.3; 95% CI, 1.4-3.9; P ¼ .002). In asymptomatic patients, anemic and nonanemic patients had comparable 30-day mortality rates (0.9% vs 0.6%; P ¼ .2). After adjustment, anemia was not associated with 30-day mortality in asymptomatic patients (OR, 1.0; 95% CI, 0.5-2.0; P ¼ .9), nor did we identify an interaction between anemia and perioperative transfusion in asymptomatic patients (P ¼ .1). Patients who received a preoperative transfusion had a higher 30-day mortality rate than anemic patients not receiving preoperative transfusion in both symptomatic (n ¼ 31, 9.7% vs 2.5%; P ¼ .04) and asymptomatic patients (n ¼ 21, 9.5% vs 0.9%; P ¼ .02).
Conclusions: Preoperative anemia is a risk factor for 30-day mortality after CEA in symptomatic patients but not in asymptomatic patients. These results should be factored into the selection of symptomatic patients for CEA and dissuade treatment of asymptomatic patients scheduled for CEA who need a preoperative transfusion. (J Vasc Surg 2018; 67:183-90.) More than one in three patients undergoing surgery have anemia, 1 and the prevalence of anemia is projected to increase because of the exponential growth of the elderly population, of whom nearly half suffer from anemia. [2] [3] [4] This is cause for concern as anemia is associated with increased morbidity and mortality after surgery. 1, 5 Because the goal of carotid endarterectomy (CEA) is the prevention of future stroke and death, anemia has the potential to diminish this intended benefit by increasing the risk of postoperative death and stroke. However, the impact of preoperative anemia on outcomes after CEA in symptomatic and asymptomatic patients is unknown. In addition to anemia, the use of blood transfusions for the treatment of anemia has also been shown to increase morbidity and mortality for patients undergoing 6, 7 These findings led to the introduction of restrictive blood transfusion protocols using a lower hemoglobin threshold for transfusion in clinical practice. 8 However, several recent studies found no difference between restrictive and liberal blood transfusion protocols in early or late survival after orthopedic and cardiac surgery. [8] [9] [10] As such, we hypothesized that it is not the combination of anemia with transfusions that results in worse outcomes after surgery but that anemia itself is an independent risk factor for perioperative complications. However, the impact of anemia, blood transfusions, and their interaction on outcomes after CEA has not been evaluated. [11] [12] [13] Thus, our aim was to compare 30-day adverse event rates, in particular mortality, stroke, and myocardial infarction (MI), after CEA between patients with and without preoperative anemia. Subsequently, we assessed effect modification between anemia and perioperative transfusion on 30-day adverse events.
METHODS
Registry. We used the Targeted Vascular module of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) registry for this analysis. The goal of the ACS NSQIP is to improve the quality of surgical care by prospectively recording 30-day postoperative outcomes in a national clinical registry. The Targeted Vascular module is a subset of ACS NSQIP that captures patients undergoing certain vascular procedures to include additional procedure-related clinical variables and disease-specific outcomes, chosen by vascular surgeons. Trained clinical reviewers categorize procedures using Current Procedural Terminology codes and collect data on predefined variables from medical charts, operative case logs, and, if necessary, letters or phone calls to patients to ensure complete 30-day follow-up. The reliability of ACS NSQIP data collection has been validated previously. 14, 15 Recommendation: This study suggests that preoperative anemia carries a higher mortality risk in symptomatic patients who undergo carotid endarterectomy.
elevation, new left bundle branch block, or new Q wave in two or more leads) or when there was a threefold increase in troponin level. All other variables were nonmodifiable, as these were predefined by the ACS NSQIP before data collection and can be found in the online user guide (www.facs.org/quality-programs/acs-nsqip/ program-specifics/participant-use).
Statistical analysis. We stratified patients by preoperative symptom status and compared them by presence of preoperative anemia. We presented categorical variables as counts and percentages and continuous variables as mean 6 standard deviation or median and IQR, where appropriate. To assess differences between groups in our univariate analysis, we used the c 2 and
Fisher exact tests for categorical variables and Student t-test and Mann-Whitney U test for continuous variables, where appropriate. We performed multivariable logistic regression, which adjusted for age, gender, dependent functional status, preprocedural stroke vs preprocedural transient ischemic attack (among symptomatic patients), diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), hypertension, congestive heart failure, and dialysis, to test the independent association between anemia and our primary and secondary outcomes. 19, 20 Using purposeful selection, we identified variables for inclusion in our models, which combine previously identified risk factors with significant covariates and confounders. 19 We did not adjust for perioperative transfusions in our initial multivariable models because perioperative transfusions likely act as a mediator between anemia, our independent variable, and mortality, our dependent variable. Therefore, adjusting for perioperative transfusions would eliminate a large proportion of the effect of anemia. Without adjusting for perioperative transfusion, we were able to capture both the mediated effect through perioperative transfusion and the nonmediated portion of the effect of anemia. As a result, we were able to assess the effect of anemia on 30-day mortality after CEA without underestimating or overestimating its risk.
However, to determine both the mediated and nonmediated part of the effect of anemia, we assessed whether the effect of anemia differed significantly between patients who received a perioperative transfusion and those who did not for 30-day mortality. Within this multivariable model, we introduced an interaction term, which assessed the interaction between preoperative anemia and perioperative transfusions, with nonanemic patients as the referent group. For our interaction analysis, we adjusted for the same variables as in the initial multivariable model. Because we were unable to exclude strokes or MIs that occurred before the perioperative transfusion, we have limited our analysis to assess the interaction between perioperative transfusion and preoperative anemia on 30-day mortality, as no transfusion can or did occur after the event of death.
As subanalysis, we further divided anemic patients into six groups based on their preoperative HCT value, similar to prior studies: $36% HCT, 35.9% to 33% HCT, 32.9% to 30% HCT, 29.9% to 27% HCT, 26.9% to 24% HCT, and <24% HCT. 16, 17 Subsequently, we analyzed the crude 30-day mortality rates over the six groups, for both symptomatic and asymptomatic patients, to better understand the relationship between the severity of anemia and 30-day mortality.
In addition, in a separate analysis, we re-entered the previously excluded patients who received a preoperative transfusion and compared them with anemic patients included in our main analysis on 30-day mortality rates, regardless of the presence of anemia in preoperatively transfused patients, because their preoperative HCT values were unreliable. We evaluated the stability of all models with the HosmerLemeshow test. Associations with a P value < .05 were considered significant. All statistical analyses were performed with SPSS version 22.0 statistical software (IBM, Armonk, NY).
RESULTS
Of 16,068 patients, 6246 (39%) were female, the mean age was 71.0 years (standard deviation, 69.2), and 290 (1.8%) patients received a perioperative transfusion. There were 6734 (42%) symptomatic patients, 1500 (22%) had preoperative anemia, and 126 (1.9%) of all symptomatic patients received a perioperative transfusion. Of the 9334 asymptomatic patients, 1935 (21%) had preoperative anemia, and 164 (1.8%) of all asymptomatic patients received a perioperative transfusion.
Patient characteristics and outcomes
Symptomatic patients. Table I shows the baseline patient characteristics and operative details, stratified by symptom status. Among symptomatic patients, those with preoperative anemia, compared with those without, were older, less often male or white, and more likely to have a dependent functional status. Comorbidities (eg, DM, hypertension, congestive heart failure, COPD, and dialysis) were more common in symptomatic patients with anemia compared with nonanemic symptomatic patients. Among symptomatic patients, those with anemia were more likely than those without anemia to have a stroke (48% vs 44%; P ¼ .002) as their preoperative neurologic event and had a higher modified Rankin Scale score (median [IQR], 2 [1-3] vs 1 [1-2]; P < .001). Type of anesthesia, CEA type (ie, patch use, shunt use, and eversion CEA), and procedure duration were comparable between anemic and nonanemic, symptomatic patients. Perioperative transfusions were more common in symptomatic patients with anemia compared with nonanemic symptomatic patients (7.0% vs 0.4%; P < .001).
On univariate analysis, 30-day mortality (2.5% vs 0.7%; P < .001) and 30-day MI rate (1.7% vs 0.8%; P ¼ .001) were higher in symptomatic patients with preoperative anemia compared with nonanemic symptomatic patients (Table II) . The 30-day stroke rate was comparable between anemic and nonanemic symptomatic patients (3.5% vs 2.9%; P ¼ .2).
After adjustment, preoperative anemia was associated with a higher odds of 30-day mortality (odds ratio [OR], 2.7; 95% confidence interval [CI], 1.7-4.4; P < .001) and 30-day MI (OR, 2.0; 95% CI, 1.2-3.4; P ¼ .01) in symptomatic patients (Table III) but not with 30-day stroke.
In the relationship between preoperative HCT and crude 30-day mortality rates in symptomatic patients, we found an upward trend for any 3% decrease in HCT below 36%, ranging from 1.8% for 35.9% to 33% HCT to 4.8% for <24% HCT (Fig) . Asymptomatic patients. Among asymptomatic patients, those with preoperative anemia compared with those without were older, more often female, and more likely to have a dependent functional status. Asymptomatic patients with anemia compared with nonanemic asymptomatic patients more often had DM, hypertension, congestive heart failure, COPD, and dialysis and were less likely to take antiplatelet therapy preoperatively. Type of anesthesia and procedure duration were comparable between anemic and nonanemic asymptomatic patients. Among asymptomatic patients, those with anemia were more likely to receive perioperative transfusions than those without anemia (5.8% vs 0.7%; P < .001).
In asymptomatic patients, 30-day MI rate (1.8% vs 1.1%; P ¼ .04) was higher in patients with preoperative anemia than in nonanemic asymptomatic patients on univariate analysis (Table II) . There were no differences between anemic and nonanemic asymptomatic patients for 30-day mortality (0.9% vs 0.5%; P ¼ .1) and 30-day stroke (1.1% vs 1.4%; P ¼ .5). On multivariable analysis, preoperative anemia was not associated with 30-day mortality (OR, 1.0; 95% CI, 0.5-2.0; P ¼ .9), 30-day stroke, or 30-day MI in asymptomatic patients (Table III) .
Moreover, in asymptomatic patients, we observed no trend for the relationship between crude 30-day mortality rates and any 3% decrease in HCT below 36%, with 0.9% for 35.9% to 33% HCT and 0.0% for <24% or <26.9% HCT (Fig) .
Interaction analysis
Among symptomatic patients, after adjustment, we found a significant interaction between preoperative anemia and perioperative transfusion for 30-day mortality (P ¼ .004).
In symptomatic patients, with nonanemic patients as the reference group, both preoperative anemia in the absence of perioperative transfusion (OR, 2.3; 95% CI, 1.4-3.9; P ¼ .002) and preoperative anemia with perioperative transfusion (OR, 7.8; 95% CI, 3.4-18.0; P < .001) were associated with 30-day mortality (Table IV) . Among asymptomatic patients, after adjustment, we did not found a significant interaction between preoperative anemia and perioperative transfusion for mortality (P ¼ .1; Table IV ).
Outcomes after preoperative transfusion
We added the patients who received a preoperative blood transfusion to our sample, irrespective of their preoperative HCT value, which resulted in 6765 symptomatic patients, of whom 31 (0.5%) received a preoperative transfusion, and 9355 asymptomatic patients, of whom 21 (0.2%) received a preoperative transfusion. When we compared anemic patients with those patients who received a preoperative transfusion, we found that both symptomatic and asymptomatic patients who received a preoperative transfusion had a higher 30-day mortality rate than symptomatic or asymptomatic patients with anemia who did not receive a preoperative transfusion (symptomatic, 9.7% vs 2.5% [P ¼ .04]; asymptomatic, 9.5% vs 0.9% [P ¼ .02]), whereas rates of 30-day stroke (symptomatic, 3.2% vs 3. 
DISCUSSION
In this study, independent of presenting symptoms, preoperative anemia was diagnosed in one of every five male patients and one of every three female patients scheduled for carotid revascularization. We found that preoperative anemia in symptomatic patients undergoing CEA was associated with 30-day mortality and 30-day MI but not with 30-day stroke. In addition, we identified a trend for higher 30-day mortality rates with any 3% decrease in HCT below 36% in symptomatic patients. Among asymptomatic patients, preoperative anemia was not associated with 30-day mortality, stroke, or MI, nor did we identify a trend for higher 30-day mortality rates with any 3% HCT reduction below 36%. In addition, we identified a significant interaction between preoperative anemia and perioperative transfusions on 30-day mortality in symptomatic patients, whereas preoperative transfusion was associated with excessively high 30-day mortality in both symptomatic and asymptomatic CEA patients.
After adjustment, symptomatic patients with preoperative anemia had a 2.7 times higher mortality risk and two times higher MI risk compared with nonanemic symptomatic patients. However, we were unable to adjust for blood loss in our analysis because the ACS NSQIP does not capture intraoperative blood loss. Therefore, we performed an additional analysis to assess the nonmediated effect of preoperative anemia by excluding all patients who received a perioperative transfusion, thus minimizing potential confounding by major intraoperative blood loss. In this subset of symptomatic patients, we still found an association between preoperative anemia and 30-day mortality but not for 30-day MI.
Contrary to symptomatic patients, we found no association on univariate or multivariable analysis between preoperative anemia and mortality in asymptomatic patients. To quantify this difference between symptomatic and asymptomatic patients, we assessed whether the association between anemia and mortality differed significantly between symptomatic and asymptomatic patients in our initial multivariable model. Subsequently, we found a significant interaction between preoperative anemia and symptom status on 30-day mortality (interaction: P < .001; symptomatic patients: OR, 2.5; 95% CI, 1.6-3.9; P < .001; asymptomatic patients: OR, 1.2; 95% CI, 0.7-2.1; P ¼ .5). Thus, symptom status appears to be an effect modifier for the relationship between preoperative anemia and 30-day mortality after CEA. However, these observations are difficult to put into perspective as there are few prior studies investigating the impact of anemia on outcomes after CEA stratified by symptom status.
Moreover, because the prevalence of anemia was higher in female patients, we assessed whether the effect of anemia on 30-day mortality was different in men and women by performing an additional interaction analysis on gender and found that the effect of anemia on mortality was similar between men and women, with an interaction of P ¼ .3 in symptomatic patients and P ¼ .3 in asymptomatic patients. Thus, although the prevalence of anemia might be higher in female CEA patients, their associated risk with anemia is the same as for male patients. One prior study of outcomes after elective vascular procedures in elderly patients reported an increased 30-day mortality risk for anemic patients undergoing CEA. 3 However, no stratification on symptom status was performed, nor did they account for blood transfusions.
The relationship between preoperative anemia, perioperative transfusion, and higher rates of 30-day mortality we found in symptomatic patients is comparable to prior studies, which identified an association between perioperative blood transfusion and worse outcomes after cardiac and noncardiac surgery. 6, 7, 12, 21 However, in asymptomatic patients, we found no interaction between preoperative anemia and perioperative transfusion on 30-day mortality. This difference between symptomatic and asymptomatic patients is likely related to the impact of symptom status on the effect of anemia. In our study, regardless of patients' preoperative HCT values, perioperative transfusions were associated with 30-day mortality in both symptomatic and asymptomatic patients when assessed in our multivariable model (Supplementary  Table, online only). However, among symptomatic patients, preoperative anemia was a risk factor for 30-day mortality independent of whether patients received a perioperative transfusion. Our finding that patients who received preoperative transfusions had higher 30-day mortality rates has also been observed in patients undergoing colorectal surgery. 22 This is cause for concern because the benefit of CEA in stroke and death prevention is directly influenced by perioperative outcomes; as such, the benefit of CEA in the case of asymptomatic patients in particular but also symptomatic patients who received preoperative transfusions is questionable. Moreover, in asymptomatic patients, the timing of the procedure can be deferred without harm, thus providing ample time to correct the preoperative low HCT by conventional treatments, as iron supplementation has been shown to reduce the need for blood transfusions in colorectal surgery. 23 The results of this study must be interpreted within the context of its design. Several limitations are inherent to the ACS NSQIP registry. We performed a retrospective analysis of prospectively collected data. First, this design does not obviate bias as a randomized trial would. However, we were able to account for this in part by our large sample size, which allowed adjusted analysis. Second, the registry collected data on a set of predefined variables, precluding additional analysis based on intraoperative blood loss and HCT value at time of transfusion, as neither is captured. However, major bleeding complications after CEA are rare, occurring in <1% of patients. 24 Therefore intraoperative blood loss is less likely to drive perioperative transfusions in patients undergoing CEA compared with other noncardiac surgical procedures. 21 Third, only a few patients had a preoperative HCT below 27%; thus, our finding that lower HCT values did not correlate with an increase in 30-day mortality in asymptomatic patients might be reflective of the small number of asymptomatic patients with a HCT <27%. Fourth, because the NSQIP registry does not capture data on the duration between the onset of neurologic symptoms and index procedure, it is possible that a proportion of symptomatic patients were identified as symptomatic, whereas their preprocedural neurologic symptom might have predated their procedure by >6 months. However, this would lead us to underestimate the interaction between symptom status and the effect of anemia on 30-day mortality. Despite these limitations, our study did provide one of the largest samples of patients undergoing CEA with anemia, allowing adjusted analysis with an interaction term for transfusions, stratified by symptom status. These results should be factored into the selection of symptomatic patients for CEA as the benefit of CEA may be limited in those patients who have a low preoperative HCT. Moreover, the selection of asymptomatic patients for CEA who need a preoperative transfusion should be dissuaded, as the benefit of CEA is lost in those asymptomatic patients who received a preoperative transfusion.
CONCLUSIONS
In this study, independent of presenting symptoms, one of five male patients and one of three female patients scheduled for carotid revascularization had preoperative anemia, which was a risk factor for 30-day mortality in symptomatic patients but not in asymptomatic patients. In addition, both symptomatic and asymptomatic patients who received a preoperative transfusion had a high 30-day mortality rate. 
